Compare ACADIA Pharmaceuticals Inc. (ACAD) vs KraneShares Electric Vehicles and Future Mobility (KARS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs KraneShares Electric Vehicles and Future Mobility — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.82 (market cap $4.49B), while KraneShares Electric Vehicles and Future Mobility trades at $30. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals.
| ACAD | KARS | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Sector/Thematic |
52-Week High | $28.06 | $38.01 |
52-Week Low | $20.06 | $22.17 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
KARS trades at $31.79, up 1.18% with a bearish technical signal as moving averages indicate selling pressure. The electric vehicle ETF faces industry headwinds including shifting consumer demand and geopolitical tensions affecting fuel prices. Recent news highlights Chinese EV expansion and regulatory uncertainties in the US market, while technical indicators show neutral oscillators but strong bearish momentum from moving averages.
The outlook remains cautious with industry pressures from Chinese competition and regulatory delays. Investment opportunities exist in global EV adoption trends, but risks include tariff policies and demand volatility. Key support sits at $31 with resistance at $32, requiring close monitoring of auto industry developments and policy changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →
